Clinical trials
catalyst calendar across sponsors →Studies where DYN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 11 tracked-famous managers (MARSHALL WACE, LLP, CITADEL ADVISORS LLC, Artisan Partners Limited Partnership, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, +6 more) · FINRA short interest 7.2 days to cover (settled 2026-07-31) · insider 90d: 3 buys / 24 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingNCT05524883Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: DYNE-251, Placebo | Duchenne Muscular Dystrophy (DMD) | 86 | Sep 2031 | ≤ 1,868 d | 2026-08-11 |
| Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)NCT07608432Rise From Floor (RFF) velocityRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Zeleciment Rostudirsen (DYNE-251), Placebo | Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD) | 90 | Dec 2030 | ≤ 1,595 d | 2026-05-27 |
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1NCT05481879MAD Cohorts: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: DYNE-101, Placebo | Myotonic Dystrophy Type 1 (DM1) | 116 | Jul 2029 | ≤ 1,077 d | 2026-05-12 |
| Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1NCT074869345 Times Sit-To-Stand (5×STS) TimeRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: zeleciment basivarsen (DYNE-101), Placebo | Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease, Steinert | 150 | Jul 2028 | ≤ 712 d | 2026-08-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19